In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens

Tigecycline (GAR-936) and daptomycin are potent antibacterial compounds in advanced stages of clinical trials. These novel agents target multiply resistant pathogenic bacteria. Daptomycin is principally active against gram-positive bacteria, while tigecycline has broad-spectrum activity. When tested...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Petersen, Peter J., Bradford, Patricia A., Weiss, William J., Murphy, Timothy M., Sum, P. E., Projan, Steven J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2002
Gaiak:
Susceptibility
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC127327/
https://ncbi.nlm.nih.gov/pubmed/12121938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.46.8.2595-2601.2002
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak